|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.38 AUD | -5.95% |
|
-4.77% | -10.12% |
| Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
| Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Page 1 of 4
SCENESSE® to be evaluated in XP-V
Page 2 of 4
SCENESSE® to be evaluated in XP-V
Page 3 of 4
SCENESSE® to be evaluated in XP-V
Page 4 of 4
SCENESSE® to be evaluated in XP-V
Attachments
Disclaimer
Clinuvel Pharmaceuticals Limited published this content on 24 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 March 2021 11:24:11 UTC.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.12% | 493M | |
| -5.99% | 84.46B | |
| +2.76% | 40.85B | |
| -24.88% | 27.69B | |
| +53.61% | 24.28B | |
| -8.08% | 17.09B | |
| -33.74% | 13.67B | |
| -16.63% | 11.86B | |
| -11.19% | 11.79B | |
| -2.25% | 8.07B |
CLINUVEL PHARMACEUTICALS LIMITED 
